| Literature DB >> 34456134 |
Brett Story1, Toloo Taghian2, Jillian Gallagher3, Jey Koehler4, Amanda Taylor5, Ashley Randle1, Kayly Nielsen1, Amanda Gross1, Annie Maguire6, Sara Carl1, Siauna Johnson1, Deborah Fernau3, Elise Diffie1, Paul Cuddon7, Carly Corado8, Sundeep Chandra8, Miguel Sena-Esteves9, Edwin Kolodny10, Xuntian Jiang11, Douglas Martin12, Heather Gray-Edwards13.
Abstract
Tay-Sachs disease (TSD) is a fatal neurodegenerative disease caused by a deficiency of the enzyme β-N-acetylhexosaminidase A (HexA). TSD naturally occurs in Jacob sheep is the only experimental model of TSD. TSD in sheep recapitulates neurologic features similar to juvenile onset and late onset TSD patients. Due to the paucity of human literature on pathology of TSD, a better natural history in the sheep TSD brain, which is on the same order of magnitude as a child's, is necessary for evaluating therapy and characterizing the pathological events that occur. To provide clinicians and researchers with a clearer understanding of longitudinal pathology in patients, we compare spectrum of clinical signs and brain pathology in mildly symptomatic (3-months), moderately symptomatic (6-months), or severely affected TSD sheep (humane endpoint at ~9-months of age). Increased GM2 ganglioside in the CSF of TSD sheep and a TSD specific biomarker on MRS (taurine) correlate with disease severity. Microglial activation and reactive astrocytes were observed globally on histopathology in TSD sheep with a widespread reduction in oligodendrocyte density. Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI. GM2 and GM3 ganglioside were increased and distributed differently in various tissues. The study of TSD in the sheep model provides a natural history to shed light on the pathophysiology of TSD, which is of utmost importance due to novel therapeutics being assessed in human patients.Entities:
Keywords: Large animal model; Neurodegeneration; Sheep; Tay-Sachs; Translational; Veterinary
Mesh:
Year: 2021 PMID: 34456134 PMCID: PMC8811770 DOI: 10.1016/j.ymgme.2021.08.009
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.204